Donna Headlee
- Oncology top 2%
- Cancer Treatment and Pharmacology 5
- Peptidase Inhibition and Analysis 3
- Biotechnology top 2%
- Genetics top 5%
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism 4
- Cancer, Lipids, and Metabolism 3
- Molecular Biology top 5%
- Cancer therapeutics and mechanisms 3
-
- Prostate Cancer Treatment and Research 8
-
- Toxin Mechanisms and Immunotoxins 4
-
- Radiopharmaceutical Chemistry and Applications 3
- Co-authors
- William D. FiggEdward A. SausvilleAdrian M. SenderowiczA TompkinsSusan G. ArbuckSeth M. SteinbergMichael R. CooperAlain Thibault
- Cited by
- OncologyBiotechnologyGenetics
- Journals
- Journal of Clinical Oncology (5 papers)Cancer (4 papers)Cancer Chemotherapy and Pharmacology (3 papers)
- Partner nations
- United StatesMalaysiaJapan
In The Last Decade
Donna Headlee
34 papers receiving 2.6k citations
Peers
Comparison fields: 5 of 97
- Oncology 1.1k
- Biotechnology 205
- Genetics 236
- Cancer Research 328
- Molecular Biology 1.5k
Countries citing papers authored by Donna Headlee
This map shows the geographic impact of Donna Headlee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna Headlee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna Headlee more than expected).
Fields of papers citing papers by Donna Headlee
This network shows the impact of papers produced by Donna Headlee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna Headlee. The network helps show where Donna Headlee may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Donna Headlee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 15 | |
| 2 | A first in human trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients. | 2004 | 2 |
| 3 | 2004 | 18 | |
| 4 | 2003 | 20 | |
| 5 | 2003 | 36 | |
| 6 | 1999 | 95 | |
| 7 | A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. | 1999 | 78 |
| 8 | 1998 | 338 | |
| 9 | 1998 | 71 | |
| 10 | Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. | 1998 | 20 |
| 11 | Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer. | 1997 | 11 |
| 12 | 1996 | 23 | |
| 13 | 1996 | 34 | |
| 14 | 1996 | 9 | |
| 15 | 1995 | 63 | |
| 16 | 1995 | 40 | |
| 17 | 1995 | 29 | |
| 18 | 1995 | 53 | |
| 19 | 1995 | 110 | |
| 20 | 1994 | 23 |
About Donna Headlee
Donna Headlee is a scholar working on Genetics, Cancer Research and Oncology, having authored 34 papers that have together received 2.7k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (8 papers), Cancer Treatment and Pharmacology (5 papers), Cancer, Hypoxia, and Metabolism (4 papers), Toxin Mechanisms and Immunotoxins (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Cancer therapeutics and mechanisms (3 papers), Peptidase Inhibition and Analysis (3 papers) and Cancer, Lipids, and Metabolism (3 papers). The work is most often cited by research in Oncology (1.1k citations), Biotechnology (205 citations) and Genetics (236 citations). Donna Headlee has collaborated with scholars based in United States, Malaysia and Japan. Frequent co-authors include William D. Figg, Edward A. Sausville, Adrian M. Senderowicz, A Tompkins, Susan G. Arbuck, Seth M. Steinberg, William D. Figg, Michael R. Cooper, Alain Thibault and Richard M. Lush. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Cancer Chemotherapy and Pharmacology, Blood and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.